Johnson & Johnson’s Cypher drug eluting Stent: Improvement and Patent infringement

Tuesday, November 1, 2011 - 6:30pm

Team Inno5
Team Inno5: Xin Hang, Jessica Morden, Faizan Rahim, Jonathan Sawatsky, Olga Vorobyova

   

Approximately a million coronary stent insertions are performed annually worldwide to treat coronary heart disease. Drug-eluting stents (DES) were developed to address the issues of thrombosis and restenosis associated with bare metal stents in the treatment of coronary heart disease. These stents release anti-proliferative and immunosuppressant drugs and were successful in reducing restenosis. DES transformed the medical device industry as Johnson & Johnson’s Cypher was the first combination product to be approved by the FDA. DES became one of the main drivers of the medical device industry with annual sales of over $4.3 billion. Since the introduction of Cypher in 2003, over four million cardiovascular patients have been treated with this device. Despite the success of Cypher in reducing restenosis, Johnson & Johnson did not benefit from market exclusivity for long. This was due to the emergence of competing DES such as Boston Scientific’s Taxus Express II stent which entered the US market eleven months later. Since the introduction of Taxus Express II, there have been many patent infringement lawsuits between multiple competitors including Johnson & Johnson and Boston Scientific over the design of DES. These patent lawsuits dispute the nature of the stent structures, eluted drugs and polymer coatings claimed. The presentation will discuss three patent infringement lawsuits, outlining the realm of patent law and exploring whether or not medical device defensibility is strengthened by the incorporation of drugs to create combination products.

Presented by Team Inno5
Tuesday, November 1, 2011
6:30-7:30pm, Instructional Centre, Room 335